tideglusib
Small moleculeexperimental
Tideglusib is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor. — Wikipedia
Clinical trial activity
10 trials · 16 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT00948259)
Timeline
Indications
Mechanism of action
- Glycogen synthase kinase-3 betaINHIBITOR
GSK3B inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1- Mol. weight
- 334.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTideglusib ↗
- ChEMBLCHEMBL3545157 ↗
Also known as
- np031112
- np031112
- np031112
- np 031112
- np-031112
- np-031112
- np-031112
- np-12
- np-12
- np-12 compound
- tideglusib
- tideglusib
- tideglusib
- tideglusib
- tideglusib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06174220 | Phase 2 | Feb 1, 2024 | AMO Pharma Limited, Canadian Institutes of Health Research (CIHR), Hamilton Health Sciences Corporation, McMaster University |
| NCT05105958 | Phase 2 | Dec 1, 2021 | Cantonal Hospital of St. Gallen, University of Bern, University of Geneva, University of Lausanne, University of Zurich |
| NCT05004129 | Phase 2/Phase 3 (Phase 3) | Aug 23, 2021 | AMO Pharma Limited |
| NCT03692312 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2018 | AMO Pharma Limited |
| NCT02858908 | Phase 2 | Aug 4, 2016 | AMO Pharma Limited, Newcastle University |
| NCT02586935 | Phase 2 | Dec 1, 2015 | McMaster University, University of Toronto, University of Western Ontario |
| NCT01350362 | Phase 2 | Apr 1, 2011 | ICON, Noscira SA |
| NCT01049399 | N/A | Dec 1, 2009 | Noscira SA, Optum |
| NCT00948259 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2008 | JSW Life Sciences GmbH, Noscira SA |
| NCT07119775 | N/A | — | AMO Pharma Limited |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AMO Pharma Limited | For profit | 5 | 4 | 3 | 2016 |
| Noscira SA | For profit | 3 | 3 | 2 | 2008 |
| McMaster University | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Hamilton Health Sciences Corporation | Academic/Hospital | 1 | 1 | 1 | 2024 |
| ICON | For profit | 1 | 0 | 1 | 2011 |
| JSW Life Sciences GmbH | For profit | 1 | 0 | 1 | 2008 |
| Newcastle University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Optum | For profit | 1 | 0 | 1 | 2009 |
| University of Bern | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Geneva | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Western Ontario | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Zurich | Academic/Hospital | 1 | 0 | 1 | 2021 |
16 organizations
Page 1 / 1